Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trial.
Bonavia A, Levi M, Rouha H, Badarau A, Terstappen J, Watson S, Anderson AB, White JT, Ananworanich J, Taylor D, Radivojevic A, Shaffer M, Stamm LM, Dunne MW. Bonavia A, et al. Among authors: stamm lm. BMC Infect Dis. 2024 Dec 3;24(1):1378. doi: 10.1186/s12879-024-10120-w. BMC Infect Dis. 2024. PMID: 39627701 Free PMC article. Clinical Trial.
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study.
Agarwal K, Xu J, Gane EJ, Nguyen TT, Ding Y, Knox SJ, Alves K, Evanchik M, Zomorodi K, Ma J, Yan R, Huang Q, Colonno R, Stamm LM, Hassanein TI, Kim DJ, Lim YS, Yuen MF. Agarwal K, et al. Among authors: stamm lm. J Viral Hepat. 2023 Mar;30(3):209-222. doi: 10.1111/jvh.13764. Epub 2023 Jan 12. J Viral Hepat. 2023. PMID: 36302125 Clinical Trial.
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes.
Peters MG, Yuen MF, Terrault N, Fry J, Lampertico P, Gane E, Hwang C, Stamm LM, Leus M, Maini MK, Mendez P, Lonjon-Domanec I, Berg T, Wang S, Mishra P, Donaldson E, Buchholz S, Miller V, Lenz O. Peters MG, et al. Among authors: stamm lm. Clin Infect Dis. 2024 Apr 10;78(4):983-990. doi: 10.1093/cid/ciad506. Clin Infect Dis. 2024. PMID: 37633256 Free PMC article.
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses.
Yuen MF, Fung S, Ma X, Nguyen TT, Hassanein T, Hann HW, Elkhashab M, Nahass RG, Park JS, Jacobson IM, Ayoub WS, Han SH, Gane EJ, Zomorodi K, Yan R, Ma J, Knox SJ, Stamm LM, Bonacini M, Weilert F, Ramji A, Bennett M, Ravendhran N, Chan S, Dieterich DT, Kwo PY, Schiff ER, Bae HS, Lalezari J, Agarwal K, Sulkowski MS. Yuen MF, et al. Among authors: stamm lm. JHEP Rep. 2024 Jan 18;6(4):100999. doi: 10.1016/j.jhepr.2023.100999. eCollection 2024 Apr. JHEP Rep. 2024. PMID: 38510983 Free PMC article.
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Yuen MF. Sulkowski MS, et al. Among authors: stamm lm. J Hepatol. 2022 Nov;77(5):1265-1275. doi: 10.1016/j.jhep.2022.05.027. Epub 2022 Jun 11. J Hepatol. 2022. PMID: 35697332 Free article. Clinical Trial.
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
Yuen MF, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Sulkowski MS. Yuen MF, et al. Among authors: stamm lm. J Hepatol. 2022 Sep;77(3):642-652. doi: 10.1016/j.jhep.2022.04.005. Epub 2022 Apr 20. J Hepatol. 2022. PMID: 35460726 Free article. Clinical Trial.
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.
Sood A, Duseja A, Kabrawala M, Amrose P, Goswami B, Chowdhury A, Sarin SK, Koshy A, Hyland RH, Lu S, Camus G, Stamm LM, Brainard DM, Subramanian GM, Prasad M, Bhatia S, Shah SR, Kapoor D, Shalimar, Saraswat V. Sood A, et al. Among authors: stamm lm. Hepatol Int. 2019 Mar;13(2):173-179. doi: 10.1007/s12072-019-09927-6. Epub 2019 Feb 21. Hepatol Int. 2019. PMID: 30790229 Free PMC article. Clinical Trial.
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
Ruane P, Strasser SI, Gane EJ, Hyland RH, Shao J, Dvory-Sobol H, Tran T, Stamm LM, Brainard DM, Nyberg L, Shafran S. Ruane P, et al. Among authors: stamm lm. J Viral Hepat. 2019 Jun;26(6):770-773. doi: 10.1111/jvh.13067. Epub 2019 Feb 27. J Viral Hepat. 2019. PMID: 30663168 Free PMC article. Clinical Trial.
54 results